[1]
|
Pardeshi, R., et al. (2017) Insulin Signaling: An Opportunistic Target to Minify the Risk of Alzheimer’s Disease. Psychoneuroendocrinology, 83, 159-171.
https://doi.org/10.1016/j.psyneuen.2017.05.004
|
[2]
|
de la Monte, S.M. and Wands, J.R. (2008) Alzheimer’s Disease Is Type 3 Diabetes-Evidence Reviewed. Journal of Diabetes Science and Technology, 2, 1101-1113. https://doi.org/10.1177/193229680800200619
|
[3]
|
De Felice, F.G., Lourenco, M.V. and Ferreira, S.T. (2014) How Does Brain Insulin Resistance Develop in Alzheimer’s Disease? Alzheimer’s & Dementia, 10, S26-32.
https://doi.org/10.1016/j.jalz.2013.12.004
|
[4]
|
LaFerla, F.M., Green, K.N. and Oddo, S. (2007) Intracellular Amyloid-Beta in Alzheimer’s Disease. Nature Reviews. Neuroscience, 8, 499-509.
https://doi.org/10.1038/nrn2168
|
[5]
|
Hardy, J. and Selkoe, D.J. (2002) The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science, 297, 353-356.
https://doi.org/10.1126/science.1072994
|
[6]
|
Akter, K., et al. (2011) Diabetes Mellitus and Alzheimer’s Disease: Shared Pathology and Treatment? British Journal of Clinical Pharmacology, 71, 365-376.
https://doi.org/10.1111/j.1365-2125.2010.03830.x
|
[7]
|
Gasparini, L., et al. (2002) Does Insulin Dysfunction Play a Role in Alzheimer’s Disease? Trends in Pharmacological Sciences, 23, 288-293.
https://doi.org/10.1016/S0165-6147(02)02037-0
|
[8]
|
Bekris, L.M., et al. (2010) Genetics of Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 23, 213-227. https://doi.org/10.1177/0891988710383571
|
[9]
|
Goldman, J.S., et al. (2011) Genetic Counseling and Testing for Alzheimer Disease: Joint Practice Guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genetics in Medicine, 13, 597-605.
https://doi.org/10.1097/GIM.0b013e31821d69b8
|
[10]
|
Francis, P.T., et al. (1999) The Cholinergic Hypothesis of Alzheimer’s Disease: A Review of Progress. Journal of Neurology, Neurosurgery, and Psychiatry, 66, 137-147. https://doi.org/10.1136/jnnp.66.2.137
|
[11]
|
Forstl, H. and Kurz, A. (1999) Clinical Features of Alzheimer’s Disease. European Archives of Psychiatry and Clinical Neuroscience, 249, 288-290.
https://doi.org/10.1007/s004060050101
|
[12]
|
Association, A.S. (2017) Alzheimer’s Association Report: 2017 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 13, 325-373.
https://doi.org/10.1016/j.jalz.2017.02.001
|
[13]
|
Hebert, L.E., et al. (2010) Change in Risk of Alzheimer Disease over Time. Neurology, 75, 786-791. https://doi.org/10.1212/WNL.0b013e3181f0754f
|
[14]
|
Baglietto-Vargas, D., et al. (2016) Diabetes and Alzheimer’s Disease Crosstalk. Neuroscience & Biobehavioral Reviews, 64, 272-287.
https://doi.org/10.1016/j.neubiorev.2016.03.005
|
[15]
|
Ma, H.R., et al. (2018) Cerebral Glucose Metabolic Prediction from Amnestic Mild Cognitive Impairment to Alzheimer’s Dementia: A Meta-Analysis. Translational Neurodegeneration, 7, 9. https://doi.org/10.1186/s40035-018-0114-z
|
[16]
|
Baumgart, M., Snyder, H.M., Carrillo, M.C., Fazio, S., Kim, H. and Johns, H. (2015) Summary of the Evidence on Modifiable Risk Factors for Cognitive Decline and Dementia: A Population-Based Perspective. Alzheimer’s & Dementia, 11, 718-726.
https://doi.org/10.1016/j.jalz.2015.05.016
|
[17]
|
Sando, S.B., et al. (2008) Risk-Reducing Effect of Education in Alzheimer’s Disease. International Journal of Geriatric Psychiatry, 23, 1156-1162.
https://doi.org/10.1002/gps.2043
|
[18]
|
Farina, N., Rusted, J. and Tabet, N. (2014) The Effect of Exercise Interventions on Cognitive Outcome in Alzheimer’s Disease: A Systematic Review. International Psychogeriatrics, 26, 9-18.
|
[19]
|
Onieva-Zafra, M. D., Hernández-Garcia, L., Gonzalez-del-Valle, M.T., Parra-Fernández, M.L. and Fernandez-Martinez, E. (2018) Music Intervention with Reminiscence Therapy and Reality Orientation for Elderly People with Alzheimer Disease Living in a Nursing Home: A Pilot Study. Holistic Nursing Practice, 32, 43-50. https://doi.org/10.1097/HNP.0000000000000247
|
[20]
|
Cacabelos, R. (2007) Donepezil in Alzheimer’s Disease: From Conventional Trials to Pharmacogenetics. Neuropsychiatric Disease and Treatment, 3, 303-333.
|
[21]
|
Olin, J. and Schneider, L. (2002) Galantamine for Alzheimer’s Disease. The Cochrane Database of Systematic Reviews, Article ID: CD001747.
|
[22]
|
Loy, C. and Schneider, L. (2006) Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment. The Cochrane Database of Systematic Reviews, Article ID: CD001747. https://doi.org/10.1002/14651858.CD001747.pub3
|
[23]
|
Cacabelos, R., Takeda, M. and Winblad, B. (1999) The Glutamatergic System and Neurodegeneration in Dementia: Preventive Strategies in Alzheimer’s Disease. International Journal of Geriatric Psychiatry, 14, 3-47.
https://doi.org/10.1002/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO;2-7
|
[24]
|
Furiya, Y., Tomiyama, T., Izumi, T., Ohba, N. and Ueno, S. (2018) Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease. Dementia and Geriatric Cognitive Disorders Extra, 8, 77-84. https://doi.org/10.1159/000487358
|
[25]
|
Eric, S., Benjamin, T.M., Enrique, J.R., et al. (2005) Impaired Insulin and Insulin-Like Growth Factor Expression and Signaling Mechanisms in Alzheimer’s Disease-Is This Type 3 Diabetes? Journal of Alzheimer's Disease, 7, 63-80.
https://doi.org/10.3233/JAD-2005-7107
|
[26]
|
Kroner, Z. (2009) The Relationship between Alzheimer’s Disease and Diabetes: Type 3 Diabetes? Alternative Medicine Review, 14, 373-379.
|
[27]
|
Gloyn, A.L. and Drucker, D.J. (2018) Precision Medicine in the Management of Type 2 Diabetes. The Lancet Diabetes & Endocrinology.
https://doi.org/10.1016/S2213-8587(18)30052-4
|
[28]
|
Toledano, Y., Hadar, E. and Hod, M. (2018) Pharmacotherapy for Hyperglycemia in Pregnancy-The New Insulins. Diabetes Research and Clinical Practice.
https://doi.org/10.1016/j.diabres.2018.04.035
|
[29]
|
Simó, R., Ciudin, A., Simó-Servat, O. and Hernández, C. (2017) Cognitive Impairment and Dementia: A New Emerging Complication of Type 2 Diabetes-The Diabetologist’s Perspective. Acta Diabetologica, 54, 417-424.
https://doi.org/10.1007/s00592-017-0970-5
|
[30]
|
Markowicz-Piasecka, M., Sikora, J., Szydłowska, A., Skupień, A., Mikiciuk-Olasik, E. and Huttunen, K.M. (2017) Metformin—A Future Therapy for Neurodegenerative Diseases: Theme: Drug Discovery, Development and Delivery in Alzheimer’s Disease Guest Editor: Davide Brambilla. Pharmaceutical Research, 34, 2614-2627.
https://doi.org/10.1007/s11095-017-2199-y
|
[31]
|
Leloup, C., Allard, C., Carneiro, L., Fioramonti, X., Collins, S. and Pénicaud, L. (2016) Glucose and Hypothalamic Astrocytes: More than a Fueling Role? Neuroscience, 323, 110-120. https://doi.org/10.1016/j.neuroscience.2015.06.007
|
[32]
|
Biessels, G.J., Staekenborg, S., Brunner, E., Brayne, C. and Scheltens, P. (2006) Risk of Dementia in Diabetes Mellitus: A Systematic Review. The Lancet Neurology, 5, 64-74. https://doi.org/10.1016/S1474-4422(05)70284-2
|
[33]
|
Zhang, J., Chen, C.X. and Hua, S.Z., et al. (2017) An Updated Meta-Analysis of Cohort Studies: Diabetes and Risk of Alzheimer's Disease. Diabetes Research and Clinical Practice, 124, 41-47. https://doi.org/10.1016/j.diabres.2016.10.024
|
[34]
|
Peila, R., Rodriguez, B.L. and Launer, L.J. (2002) Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies: The Honolulu-Asia Aging Study. Diabetes, 51, 1256-1262. https://doi.org/10.2337/diabetes.51.4.1256
|
[35]
|
de la Monte, S.M. (2014) Type 3 Diabetes Is Sporadic Alzheimer’s Disease: Mini-Review. European Neuropsychopharmacology, 24, 1954-1960.
https://doi.org/10.1016/j.euroneuro.2014.06.008
|
[36]
|
Schulingkamp, R.J., Pagano, T.C., Hung, D. and Raffa, R.B. (2000) Insulin Receptors and Insulin Action in the Brain: Review and Clinical Implications. Neuroscience & Biobehavioral Reviews, 24, 855-872.
https://doi.org/10.1016/S0149-7634(00)00040-3
|
[37]
|
Butterfield, D.A., Domenico, F.D. and Barone, E. (2014) Elevated Risk of Type 2 Diabetes for Development of Alzheimer Disease: A Key Role for Oxidative Stress in Brain. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1842, 1693-1706. https://doi.org/10.1016/j.bbadis.2014.06.010
|
[38]
|
Suzanne, C., et al. (1993) Effects of Hyperglycemia on Memory and Hormone Levels in Dementia of the Alzheimer Type: A Longitudinal Study. Behavioral Neuroscience, 107, 926-940. https://doi.org/10.1037/0735-7044.107.6.926
|
[39]
|
Frölich, L., et al. (1998) Brain Insulin and Insulin Receptors in Aging and Sporadic Alzheimer’s Disease. Journal of Neural Transmission, 105, 423-438.
https://doi.org/10.1007/s007020050068
|
[40]
|
de la Monte, S.M. and Tong, M. (2014) Brain Metabolic Dysfunction at the Core of Alzheimer’s Disease. Biochemical Pharmacology, 88, 548-549.
https://doi.org/10.1016/j.bcp.2013.12.012
|
[41]
|
de la Monte, S.M. (2009) Insulin Resistance and Alzheimer’s Disease. BMB Reports, 42, 475-481. https://doi.org/10.5483/BMBRep.2009.42.8.475
|
[42]
|
Kandimalla, R., Thirumala, V. and Reddy, P.H. (2017) Is Alzheimer’s Disease a Type 3 Diabetes? A Critical Appraisal. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1863, 1078-1089.
https://doi.org/10.1016/j.bbadis.2016.08.018
|
[43]
|
Akiyama, H., et al. (2000) Inflammation and Alzheimer’s Disease. Neurobiology of Aging, 21, 383-421. https://doi.org/10.1016/S0197-4580(00)00124-X
|
[44]
|
Rogers, J. and Shen, Y. (2000) A Perspective on Inflammation in Alzheimer’s Disease. Annals of the New York Academy of Sciences, 924, 132-135.
https://doi.org/10.1111/j.1749-6632.2000.tb05571.x
|
[45]
|
Mittal, K. and Katare, D.P. (2016) Shared Links between Type 2 Diabetes Mellitus and Alzheimer’s Disease: A Review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 10, S144-S149. https://doi.org/10.1016/j.dsx.2016.01.021
|
[46]
|
de la Monte, S.M., Ming, T., Nataniel, L.-C., Michael P.J. and Wands, J.R. (2006) Therapeutic Rescue of Neurodegeneration in Experimental Type 3 Diabetes: Relevance to Alzheimer’s Disease. Journal of Alzheimer’s Disease, 10, 89-109.
https://doi.org/10.3233/JAD-2006-10113
|
[47]
|
Akhtar, M.W., et al. (2016) Elevated Glucose and Oligomeric β-Amyloid Disrupt Synapses via a Common Pathway of Aberrant Protein S-Nitrosylation. Nature Communications, 7, Article ID: 10242. https://doi.org/10.1038/ncomms10242
|
[48]
|
Clodfelder-Miller, B.J., Zmijewska, A.A., Johnson, G.V.W. and Jope, R.S. (2006) Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain in Vivo after Streptozotocin-Induced Insulin Deficiency. Diabetes, 55, 3320-3325.
https://doi.org/10.2337/db06-0485
|
[49]
|
de la Monte, S.M. (2012) Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer’s Disease. Current Alzheimer Research, 9, 35-66.
https://doi.org/10.2174/156720512799015037
|
[50]
|
Spires-Jones, T.L., Stoothoff, W.H., de Calignon, A., Jones, P.B. and Hyman, B.T. (2009) Tau Pathophysiology in Neurodegeneration: A Tangled Issue. Trends in Neurosciences, 32, 150-159. https://doi.org/10.1016/j.tins.2008.11.007
|
[51]
|
Abbondante, S., Baglietto-Vargas, D., Rodriguez-Ortiz, C.J., Estrada-Hernandez, T., Medeiros, R. and LaFerla, F.M. (2014) Genetic Ablation of Tau Mitigates Cognitive Impairment Induced by Type 1 Diabetes. American Journal of Pathology, 184, 819-826. https://doi.org/10.1016/j.ajpath.2013.11.021
|
[52]
|
Thakur, A., Wang, X.L., Siedlak, S.L., Perry, G., Smith, M.A. and Zhu, X.W. (2007) C-Jun Phosphorylation in Alzheimer Disease. Journal of Neuroscience Research, 85, 1668-1673. https://doi.org/10.1002/jnr.21298
|
[53]
|
Goodpaster, B.H., et al. (2005) Obesity, Regional Body Fat Distribution, and the Metabolic Syndrome in Older Men and Women. Archives of Internal Medicine, 165, 777-783. https://doi.org/10.1001/archinte.165.7.777
|
[54]
|
Campbell, I.W. (2000) Antidiabetic Drugs Present and Future: Will Improving Insulin Resistance Benefit Cardiovascular Risk in Type 2 Diabetes Mellitus? Drugs, 60, 1017-1028. https://doi.org/10.2165/00003495-200060050-00004
|
[55]
|
Gustafson, D., et al. (2003) An 18-Year Follow-Up of Overweight and Risk of Alzheimer Disease. Archives of Internal Medicine, 163, 1524-1528.
https://doi.org/10.1001/archinte.163.13.1524
|
[56]
|
Naderali, E.K., Ratcliffe, S.H. and Dale, M.C. (2009) Obesity and Alzheimer’s Disease: A Link between Body Weight and Cognitive Function in Old Age. American Journal of Alzheimer’s Disease & Other Dementias, 24, 445-449.
https://doi.org/10.1177/1533317509348208
|
[57]
|
Femminella, G.D. and Bencivenga, L., et al. (2017) Antidiabetic Drugs in Alzheimer’s Disease: Mechanisms of Action and Future Perspectives. Journal of Diabetes Research, 2017, Article ID: 7420796.
|
[58]
|
Shingo, A.S., Kanabayashi, T., Kito, S. and Murase, T. (2012) Intracerebroventricular Administration of an Insulin Analogue Recovers STZ-Induced Cognitive Decline in Rats. Behavioural Brain Research, 241, 105-111.
|
[59]
|
Freiherr, J., et al. (2013) Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence. CNS Drugs, 27, 505-514.
https://doi.org/10.1007/s40263-013-0076-8
|
[60]
|
Landreth, G. (2007) Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimer’s Disease. Current Alzheimer Research, 4, 159-164.
https://doi.org/10.2174/156720507780362092
|
[61]
|
Wang, L., Liu, W., Fan, Y., Liu, T.T. and Yu, C.J. (2017) Effect of Rosiglitazone on Amyloid Precursor Protein Processing and Aβ Clearance in Streptozotocin-Induced Rat Model of Alzheimer’s Disease. Iranian Journal of Basic Medical Sciences, 20, 474-480.
|
[62]
|
Pancani, T., et al. (2009) Distinct Modulation of Voltage-Gated and Ligand-Gated Ca2+ Currents by PPAR-γ Agonists in Cultured Hippocampal Neurons. Journal of Neurochemistry, 109, 1800-1811. https://doi.org/10.1111/j.1471-4159.2009.06107.x
|
[63]
|
Harrington, C., et al. (2011) Rosiglitazone Does not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimer’s Disease: Two Phase 3 Studies. Current Alzheimer Research, 8, 592-606. https://doi.org/10.2174/156720511796391935
|
[64]
|
Cheng, H.W., Shang, Y.P., Jiang, L., Shi, T.-L. and Wang, L. (2016) The Peroxisome Proliferators Activated Receptor-Gamma Agonists as Therapeutics for the Treatment of Alzheimer’s Disease and Mild-to-Moderate Alzheimer’s Disease: A Meta-Analysis. International Journal of Neuroscience, 126, 299-307.
https://doi.org/10.3109/00207454.2015.1015722
|
[65]
|
Alp, H., et al. (2012) Protective Effects of Beta Glucan and Gliclazide on Brain Tissue and Sciatic Nerve of Diabetic Rats Induced by Streptozosin. Experimental Diabetes Research, 2012, Article ID: 230342.
|
[66]
|
Irons, B.K. and Minze, M.G. (2014) Drug Treatment of Type 2 Diabetes Mellitus in Patients for whom Metformin Is Contraindicated. Diabetes, Metabolic Syndrome and Obesity, 7, 15-24. https://doi.org/10.2147/DMSO.S38753
|
[67]
|
Li, S.-N., Wang, X., Zeng, Q.T., Feng, Y.B., et al. (2009) Metformin Inhibits Nuclear Factor κB Activation and Decreases Serum High-Sensitivity C-Reactive Protein Level in Experimental Atherogenesis of Rabbits. Heart Vessels, 24, 446-453.
https://doi.org/10.1007/s00380-008-1137-7
|
[68]
|
Rena, G., Pearson, E.R. and Sakamoto, K. (2013) Molecular Mechanism of Action of Metformin: Old or New Insights? Diabetologia, 56, 1898-1906.
https://doi.org/10.1007/s00125-013-2991-0
|
[69]
|
Burcelin, R. (2014) The Antidiabetic Gutsy Role of Metformin Uncovered? Gut, 63, 706-707. https://doi.org/10.1136/gutjnl-2013-305370
|
[70]
|
Chiang, M.-C., Cheng, Y.-C., Chen, S.-J., Yen, C.-H. and Huang, R.-N. (2016) Metformin Activation of AMPK-Dependent Pathways Is Neuroprotective in Human Neural Stem Cells against Amyloid-Beta-Induced Mitochondrial Dysfunction. Experimental Cell Research, 347, 322-331.
https://doi.org/10.1016/j.yexcr.2016.08.013
|
[71]
|
DiTacchio, K. (2011) The Effect of AMPK Activation on Alzheimer’s-Like Symptoms in APP Mice. University of California, San Diego.
|
[72]
|
Herath, P.M., Cherbuin, N., Eramudugolla, R. and Anstey, K.J. (2016) The Effect of Diabetes Medication on Cognitive Function: Evidence from the PATH through Life Study. BioMed Research International, 2016, Article ID: 7208429
|
[73]
|
Mostafa, D.K., Ismail, C.A. and Ghareeb, D.A. (2016) Differential Metformin Dose-Dependent Effects on Cognition in Rats: Role of Akt. Psychopharmacology, 233, 2513-2524. https://doi.org/10.1007/s00213-016-4301-2
|
[74]
|
Hettich, M.M., et al. (2014) The Anti-Diabetic Drug Metformin Reduces BACE1 Protein Level by Interfering with the MID1 Complex. PLoS ONE, 9, e102420.
https://doi.org/10.1371/journal.pone.0102420
|
[75]
|
Alzoubi, K.H., Khabour, O.F., Al-azzam, S.I., Tashtoush, M.H. and Mhaidat, N.M. (2014) Metformin Eased Cognitive Impairment Induced by Chronic L-Methionine Administration: Potential Role of Oxidative Stress. Current Neuropharmacology, 12, 186-192. https://doi.org/10.2174/1570159X11666131120223201
|
[76]
|
Arafa, N.M., Marie, M.A. and AlAzimi, S.A. (2016) Effect of Canagliflozin and Metformin on Cortical Neurotransmitters in a Diabetic Rat Model. Chemico-Biological Interactions, 258, 79-88. https://doi.org/10.1016/j.cbi.2016.08.016
|
[77]
|
Abner, E.L., et al. (2016) Diabetes Is Associated with Cerebrovascular but not Alzheimer’s Disease Neuropathology. Alzheimer’s & Dementia, 12, 882-889.
https://doi.org/10.1016/j.jalz.2015.12.006
|
[78]
|
Beeri, M.S., et al. (2005) Type 2 Diabetes Is Negatively Associated with Alzheimer’s Disease Neuropathology. Journals of Gerontology: Series A, Biological Sciences and Medical Sciences, 60, 471-475.
https://doi.org/10.1093/gerona/60.4.471
|
[79]
|
Sonnen, J.A., Larson, E.B. and LBchB, K.B., et al. (2009) Different Patterns of Cerebral Injury in Dementia with or without Diabetes. Archives of Neurology, 66, 315-322. https://doi.org/10.1001/archneurol.2008.579
|
[80]
|
Mima, Y., et al. (2016) Impact of Metformin on the Severity and Outcomes of Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus. Journal of Stroke and Cerebrovascular Diseases, 25, 436-446.
https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.10.016
|
[81]
|
Giannarelli, R., Aragona, M., Coppelli, A. and Del Prato, S. (2003) Reducing Insulin Resistance with Metformin: The Evidence Today. Diabetes & Metabolism, 29, 6S28-35.
|
[82]
|
Hsu, C.-C., Wahlqvist, M.L., Lee, M.-S. and Tsai, H.-N. (2011) Incidence of Dementia Is Increased in Type 2 Diabetes and Reduced by the Use of Sulfonylureas and Metformin. Journal of Alzheimer’s Disease, 24, 485-493.
https://doi.org/10.3233/JAD-2011-101524
|
[83]
|
Imfeld, P., Bodmer, M., Jick, S.S. and Meier, C.R. (2012) Metformin, Other Antidiabetic Drugs, and Risk of Alzheimer’s Disease: A Population-Based Case-Control Study. Journal of the American Geriatrics Society, 60, 916-921.
https://doi.org/10.1111/j.1532-5415.2012.03916.x
|
[84]
|
Guo, M., et al. (2014) Metformin May Produce Antidepressant Effects through Improvement of Cognitive Function among Depressed Patients with Diabetes Mellitus. Clinical and Experimental Pharmacology and Physiology, 41, 650-656.
|
[85]
|
McNeilly, A.D., Williamson, R., Balfour, D.J.K., Stewart, C.A. and Sutherland, C. (2012) A High-Fat-Diet-Induced Cognitive Deficit in Rats that Is Not Prevented by Improving Insulin Sensitivity with Metformin. Diabetologia, 55, 3061-3070.
https://doi.org/10.1007/s00125-012-2686-y
|
[86]
|
Qiu, W.Q. and Zhu, H. (2014) Amylin and Its Analogs: A Friend or Foe for the Treatment of Alzheimer’s Disease? Frontiers in Aging Neuroscience, 6, 186.
https://doi.org/10.3389/fnagi.2014.00186
|
[87]
|
Verdile, G., Fuller, S.J. and Martins, R.N. (2015) The Role of Type 2 Diabetes in Neurodegeneration. Neurobiology of Disease, 84, 22-38.
https://doi.org/10.1016/j.nbd.2015.04.008
|
[88]
|
Adler, B.L., et al. (2014) Neuroprotective Effects of the Amylin Analogue Pramlintide on Alzheimer’s Disease Pathogenesis and Cognition. Neurobiology of Aging, 35, 793-801. https://doi.org/10.1016/j.neurobiolaging.2013.10.076
|